Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
तुलना करने के लिए मीट्रिक्स | ACTI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधACTIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.9x | −2.5x | −0.6x | |
PEG अनुपात | −0.04 | −0.05 | 0.00 | |
क़ीमत/बुक | 24.6x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 0.0x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 275.0% | 41.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.3% | 4.8% | अनलॉक करें |